Navigation Links
Aethlon Medical, Inc. - The Launch of a Clinical Program That Re-Thinks the Treatment of Viral Pathogens
Date:2/5/2015

SAN DIEGO, Feb. 5, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today published an article on The Chairman's Blog, written by the Company's Chairman and CEO, Jim Joyce.  TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In the article, entitled "The Launch of a Clinical Program That Re-Thinks the Treatment of Viral Pathogens," Mr. Joyce discusses the increasing incidence of viral epidemics as well as patient enrollment and the launch of the Company's first FDA approved study.  Read the full article from Mr. Joyce on TheChairmansBlog.com (http://www.thechairmansblog.com/aethlon-medical/james-joyce/launch-clinical-program-re-thinks-treatment-viral-pathogens).

About Aethlon Medical, Inc.

Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease, cancer and neurodegenerative disorders.  The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.  Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including Ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com 

David Zazoff
MDM Worldwide Solutions
646-403-3554

Logo - http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b

 


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Announces the Appointment of Chetan S. Shah, M.D. to its Board of Directors
2. Aethlon Medical to Present at Exosomes and Circulating Biomarkers 2013 Summit
3. Aethlon Medical Announces Launch of Exosome Sciences Subsidiary
4. Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
5. Aethlon Medical Announces the Appointment of Dr. Cicek Gercel-Taylor as Clinical Research Director of Exosome Sciences, Inc.
6. Aethlon Medical (AEMD) Note: Cancer Immunotherapy Article, Introduction to Dr. Douglas Taylor
7. Aethlon Medical to Present at SeeThruEquity Investor Conference
8. Aethlon Medical to Present at Biotech Showcase Investor Conference
9. Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform
10. Aethlon Medical Receives Notice of DARPA Contract Renewal
11. Aethlon Medical Announces Dengue Virus Treatment Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2019)... , ... October 11, 2019 , ... Based on data ... a 9 percent increase in deceased organ donors over 2018. Through August 31, 7,786 ... Transplantation Network (OPTN) national database . At this pace, the Association of Organ ...
(Date:10/10/2019)... ... October 10, 2019 , ... ... Cocktail Reception on Thursday, September 26, at the Westchester Country Club in Rye. ... unwavering support of the organization and its mission. , “In Celebration” featured live ...
(Date:10/8/2019)... Pa. (PRWEB) , ... October 09, 2019 , ... “When ... the emotions, frustrations, and the realities of the HEMS world through telling the real ... Helicopter Pilot” is the creation of published author Jay A. Humphrey, an EMS helicopter ...
Breaking Medicine Technology:
(Date:10/15/2019)... ANGELES (PRWEB) , ... October 14, 2019 , ... An ... their teeth with salt or baking soda. The article points out that both agents ... might have been justifiable before the invention of modern toothpastes, they are also good ...
(Date:10/15/2019)... ... ... Genomenon® announced today at the American Society of Human Genetics ... Mastermind® Genomic Search Engine into the SOPHiA Platform and the Alamut ... clinical researchers performing genomic analysis worldwide. , The SOPHiA Platform is the ...
(Date:10/11/2019)... Calif. (PRWEB) , ... October 11, 2019 , ... Inland ... of Temecula, CA. The new location has incredible views of the Temecula Valley and ... On 2.5 acres, the new facility offers both private rooms as well as double ...
(Date:10/10/2019)... ... October 10, 2019 , ... Santa Rosa Consulting, Inc. ... the healthcare industry, has completed the first phase of a comprehensive strategic and ... The Bahamas towards a fully integrated health information management system (iHIMS). , ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... QFC and Fred Meyer, King Sooper, Fry’s, Roundy’s, Smiths and Dillons. , Safe ... & gluten-free. , “Ingredient purity and fresh taste is paramount for us,” ...
Breaking Medicine News(10 mins):